Table 1.

Description of randomized control trials

Study	Location	Dosing schedule	Inclusion criteria	Exclusion criteria	Total sample size, n	Primary outcome measure
STOP COVID 1	United States	50 mg on day 1, 100 mg twice daily on days 2 and 3, 100 mg three times daily on days 4–15	Unvaccinated patients ≥ 18 years Confirmed COVID-19 Symptomatic within 7 days of first dose	Having COVID-19 and requiring hospitalization or showing signs of primary outcome (clinical deterioration) Severe underlying disease Immunocompromised	152	Clinical deterioration within 15 days: shortness of breath/pneumonia and oxygen saturation < 92% or supplemental oxygen required
STOP COVID 2	United States and Canada	50 mg on day 1, 100 mg twice daily on days 2–15	Unvaccinated patients ≥ 30 years Confirmed COVID-19 test and symptomatic within 7 days of first dose One risk factor required	Having COVID-19 and requiring hospitalization or showing signs of primary outcome (clinical deterioration) Unstable medical comorbidities Taking SSRI or drugs affected by fluvoxamine	547	Clinical deterioration within 15 days: shortness of breath/pneumonia and oxygen saturation < 92%, or supplemental oxygen required
TOGETHER Trial	Brazil	100 mg twice a day for 10 days	Unvaccinated patients ≥ 18 years Confirmed COVID-19 test and symptomatic within 7 days of first dose Risk factor required	Patients treated in primary care or requiring hospitalization Patients who received vaccination Patients using SSRIs	1,497	Composite outcome within 28 days: retention in an COVID-19 emergency setting > 6 hours, or transfer to a tertiary hospital, because of COVID-19

SSRI = selective serotonin reuptake inhibitor.